$1.06
+0.09 (+9.27%)
Open$0.98
Previous Close$0.97
Day High$1.13
Day Low$0.95
52W High$5.48
52W Low$0.69
Volume—
Avg Volume47.6K
Market Cap26.97M
P/E Ratio—
EPS$-0.26
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+2,230.2% upside
Current
$1.06
$1.06
Target
$24.70
$24.70
$17.28
$24.70 avg
$43.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.17M | 1.04M | 9.21M |
| Net Income | -11,243,139 | -9,012,134 | 1.19M |
| Profit Margin | -962.1% | -914.0% | 12.9% |
| EBITDA | -9,709,254 | -8,214,990 | 1.73M |
| Free Cash Flow | — | — | 900.3K |
| Rev Growth | +12.3% | +12.3% | -0.3% |
| Debt/Equity | 1.46 | 1.46 | 0.87 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |